In a report published Thursday, Maxim Group analysts initiated coverage on Kite Pharma, Inc. (KITE) with a ‘Buy‘ rating and $87 price target.
On valuation measures, Kite Pharma Inc. shares currently have t-12 price/sales of 881.36 while EPS is ($1.72). Currently there are 8 analysts that rate KITE a ‘Buy’ versus zero rating it a ‘Hold’ or ‘Sell’. KITE has a median Wall Street price target of $83.00 with a high target of $90.00.
In the past 52 weeks, shares of Santa Monica, California-based company have traded between a low of $21.00 and a high of $89.21 and are now at $62.91. Shares are up 2.25% year-to-date.
Analysts at UBS are out with a report this morning upgrading shares of Harley-Davidson, Inc. (HOG) with a ‘Buy‘ from ‘Neutral‘ rating. The firm raised its price target for the company to $63 from $60.
Harley-Davidson Inc. shares are currently priced at 15.07x this year’s forecasted earnings. Ticker has a forward P/E of 13.43 and t-12 price-to-sales ratio of 1.93. EPS for the same period is $3.93.
In the past 52 weeks, shares of Milwaukee, Wisconsin-based company have traded between a low of $53.04 and a high of $72.37 and are now at $59.20. Shares are down 16.25% year-over-year and 13.14% year-to-date.
Analysts at Wedbush upgraded their rating on the shares of Juniper Networks, Inc. (JNPR). In a research note published on Thursday, the firm lifted the name with a ‘Outperform‘ from ‘Neutral‘ rating.
Currently there are 10 analysts that rate JNPR a ‘Buy‘, 22 rate it a ‘Hold‘. 2 analysts rate it a ‘Sell‘. JNPR has a median Wall Street price target of $26.00 with a high target of $34.00.
Supernus Pharmaceuticals, Inc. (SUPN) had its rating hiked to ‘Buy‘ from ‘Hold‘ by Jefferies today. The firm currently has a $18 price target on the stock, up from their previous price target of $11.
SUPN shares recently gained $1.27 to $17.28. The stock is up 49.77% year-over-year and has gained roughly 93% year-to-date. In the past 52 weeks, shares of Rockville, Maryland-based company have traded between a low of $7.31 and a high of $18.55.
Supernus Pharmaceuticals Inc. closed Wednesday at $16.01. The name has a current market cap of $825.34 million.
Alaska Air Group, Inc. (ALK) was upgraded to ‘Outperform‘ from ‘Neutral‘ by Credit Suisse (CS) analysts on Thursday.
ALK is currently printing a normal trading volume with the issue trading 873K shares, compared to the average volume of 1.27 million. The stock began trading this morning at $62.61 to currently trade 3.11% higher from the prior days close of $62.03. On an intraday basis it has gotten as low as $62.61 and as high as $64.37.
Alaska Air Group Inc. shares are priced at 13.13x this year’s forecasted earnings, compared to the industry’s 71.57x earnings multiple. The company’s current year and next year EPS growth estimates stand at 42.60% and 3.20% compared to the industry growth rates of 22.30% and 16.20%, respectively. ALK has a t-12 price-to-sales ratio of 1.48. EPS for the same period registers at $4.87.
ALK shares have declined 7.94% in the last 4 weeks and 8.47% in the past three months. Over the past 5 trading sessions the stock has gained 2.09%.
The Seattle, Washington-based company, which is currently valued at $8.28 billion, has a median Wall Street price target of $78.00 with a high target of $86.00. Alaska Air Group Inc. is up 32.14% year-over-year, compared with a 7.19% gain in the S&P 500.